Skip to main content
. Author manuscript; available in PMC: 2019 Jul 1.
Published in final edited form as: Clin Cancer Res. 2018 Sep 17;25(1):312–324. doi: 10.1158/1078-0432.CCR-18-0867

Fig 5. Combination of AZD8055 and ABT-263 triggers high apoptosis in T-ALL cell lines and primary T-ALL models in vitro.

Fig 5.

(A) Human T-ALL cell lines were treated with DMSO, 300 nM ABT-263, 500 nM AZD8055 or a combination of 300 nM ABT-263 and 500 nM AZD8055 for 48h, after which cells were stained with propidium iodide and Annexin-V. Apoptosis was measured by FACS analysis as percentage of cells that are Annexin-V positive. The experiment was done in triplicate and the percentage apoptosis values are shown for each treatment with mean ± SD. (B) Primary T-ALL cells from six patients were treated with DMSO, 1 μM ABT-263, 500 nM AZD8055 or a combination of 1 μM ABT-263 and 500 nM AZD8055 for 3days, after which cells were stained with propidium iodide and Annexin-V. Apoptosis was measured by FACS analysis as percentage of Annexin-V positive cells. The experiment was done in triplicate and the percentage apoptosis values are shown for each treatment with mean ± SD.